Averin Capital Acquisition

There is no operating business. The entity is a cash shell seeking to merge with an operating company. Any future moat will depend entirely on the acquired target’s competitive position and deal terms. Today’s advantages are limited to sponsor networks and deal sourcing capabilities.

There are no switching costs, network effects, or cost advantages at the SPAC level. The company is a Cayman Islands exempted entity with a 24 month clock, which limits time to build structural advantages.

No product, service, or revenue model exists at the SPAC level. Pricing power cannot be assessed until a target is announced with clear unit economics. Until then, investor returns are driven by trust value, interest earned on permitted investments, and redemption mechanics, not by pricing decisions.

Near term predictability comes only from the trust structure and redemption right. As of March 5, 2026 total cash placed in trust is about 283.86 million dollars after partial over‑allotment, equal to roughly 10 dollars per public share before taxes and permitted withdrawals.

Operating results are unknowable until a business combination is identified and approved. The 24 month completion window through approximately February 20, 2028, provides a time boundary but not business predictability.

Strength derives from the fully funded U.S. trust account invested in short dated U.S. government securities or qualifying money market funds.

The trust is restricted and cannot be used for general corporate purposes except for taxes and limited working capital from interest (up to 500,000 dollars per year, with a smaller cap in the final months if a definitive agreement is signed). There is no operating debt.

However, funds are inaccessible until a merger closes and are reduced by deferred underwriting fees and permitted withdrawals, so practical liquidity for operations is minimal.

Capital allocation to date reflects a standard SPAC: 25.0 million IPO units at 10 dollars, later upsized by a 3.386 million unit partial over‑allotment; 200,000 private placement units purchased by the sponsor; 13.75 million dollars of deferred underwriting fees; and founder promote shares that are intended to represent 20 percent of post‑IPO shares, subject to forfeiture if the over‑allotment is not fully exercised.

These terms are industry standard but structurally dilutive for public holders at de‑SPAC. No history yet of buybacks, dividends, or reinvestment returns.

Leadership is credible for sourcing in the targeted health and technology arenas. CEO and Chairman David Berry MD PhD has a long record as a company builder and investor. The independent board adds sector depth with Mary T. Szela and others.

Still, SPAC incentive structures can misalign sponsor and public shareholder outcomes if a deal is pursued mainly to crystallize the promote rather than to maximize long term value. Until a target is disclosed, execution quality remains unproven.